Form 4: NovaBay Pharmaceuticals Director Swan Sit Acquires 30,000 Restricted Stock Units

Director Swan Sit acquired 30,000 restricted stock units in NovaBay Pharmaceuticals, vesting one year from the grant date.

Summary

• On May 28, 2024, Swan Sit, a director of NovaBay Pharmaceuticals, acquired 30,000 restricted stock units (RSUs).
• Each RSU represents a contingent right to receive one share of NovaBay's common stock.
• The RSUs vest on the one-year anniversary of the grant date.
• The reported number of RSUs does not reflect the 1-for-35 reverse stock split that NovaBay implemented on May 30, 2024.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock units granted to a director. While insider ownership is generally viewed positively, this is a standard compensation practice.

Positives

• The acquisition of restricted stock units by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting of the restricted stock units is contingent upon Swan Sit's continued service as a director for one year from the grant date.

Industry Context

Form 4 filings are standard disclosures for insiders, providing transparency into their transactions in the company's securities. This particular filing reflects compensation in the form of restricted stock units, a common practice.

Stakeholder Impact

• The acquisition of RSUs by a director could have a slightly positive impact on shareholder sentiment, as it aligns the director's interests with those of the shareholders.

Key Dates

Keywords

NovaBay Pharmaceuticals, Swan Sit, restricted stock units, RSU, director, Form 4, NBY, beneficial ownership, reverse stock split